Menu Philippe sold $38K of SOPH
Menu Philippe (Chief Medical Officer) sold 5,000 shares of SOPHiA GENETICS SA (SOPH) at $7.68 on 2026-11-12 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure provides transparency on insider trading activity but does not include any new business, clinical, regulatory, or financial guidance information.
Market read
This is a routine 10b5-1 open-market sale disclosure; it is unlikely to drive a major repricing without additional corroborating news.
What to watch
The article does not state whether there were concurrent purchases, the insider’s broader trading history, or any changes in company fundamentals around the sale date.
Background
The article is an SEC Form 4 insider transaction disclosure for SOPHiA GENETICS SA.
Ticker impact
SEC Form 4 shows CMO Menu Philippe sold 5,000 SOPHiA GENETICS shares for about $38.4K under a pre-arranged 10b5-1 plan.
Likely limited impact; any reaction would be muted because the sale is explicitly under a pre-arranged 10b5-1 plan.
The filing is a routine insider transaction with disclosed mechanics (10b5-1 pre-arranged plan) and no accompanying operational or guidance change.
Market effects
Minimal; this is company-specific insider activity with no stated sector-wide catalyst.
None indicated.
None indicated.
Counterpoint
Traders may still treat insider sales as a sentiment signal, especially if multiple insiders sell around the same period, even when 10b5-1 is used.
Key entities
- issuerSOPHiA GENETICS SA
Subject of the Form 4 insider transaction disclosure.
- insiderMenu Philippe
Chief Medical Officer who executed the reported sale.



